Clinical Trial

Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
In this Phase 2, Single-Arm, Multi-Center, Open-Label Study, participants with previously treated locally advanced unresectable or metastatic solid tumors with mismatched repair deficient (dMMR) or microsatellite instability-high (MSI-H) will be treated with anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317).
Protocol Amendment History 18 amendments
This ClinicalTrials.gov record has been amended 18 times since 2018-11-08; most recent amendment 2026-07-09.
Trial Details
NCT Number NCT03736889
Lead Sponsor BeiGene
Conditions MSI-H/dMMR Solid Tumors
Enrollment 200 participants
Start Date 2018-09-19
Primary Completion 2026-11 (estimated)
Study Completion 2027-09 (estimated)
Updated on ClinicalTrials.gov 2026-07-10